Immunome (IMNM) Q3 2026 earnings summary

Executive summary

• Varegacestat’s NDA was accepted by the FDA with an April 28, 2027 PDUFA date; the EMA validated its MAA in October 2026.

• IM-1021, IM-1617 and IM-3050 are in Phase 1; IM-1340 received IND clearance, and an IM-1335 IND submission is expected in late 2026.

• IM-1021 showed a 53% ORR among 19 response-evaluable B-NHL patients, including five complete responses; dose optimization continues.

Financial highlights

• Q3 2026 operating expenses were $90.4M versus $60.1M a year earlier; net loss was $85.8M versus $57.5M, with no collaboration revenue.

• Q3 R&D expense was $69.5M versus $49.2M, including $6.6M in stock-based compensation; G&A was $20.9M versus $10.9M, including $6.2M in stock-based compensation.

• 9M 2026 operating expenses were $227.8M versus $158.2M; net loss was $212.7M versus $142.5M, and collaboration revenue was zero versus $6.9M.

• 9M operating cash use was $181.1M; quarter-end cash, cash equivalents and restricted cash were $213.1M, with $248.7M of marketable securities.

Outlook and guidance

• Cash, cash equivalents and marketable securities were expected to fund planned operations and capital expenditures for at least 12 months from the filing date; management cited runway into 2028.

• Expenses are expected to rise substantially as varegacestat advances through review and potential launch, clinical programs progress, manufacturing scales and discovery expands.

• IM-1340 Phase 1 initiation is planned by year-end 2026; an IM-1335 IND submission is expected in late 2026, with an updated IM-1021 dataset expected at ASH on Dec. 14, 2026.